Compare ProShares Ultra Silver ETF (AGQ) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares Ultra Silver ETF vs Pfizer Inc — how do they compare? ProShares Ultra Silver ETF trades at $82.1, while Pfizer Inc trades at $26.33 (market cap $151.73B). The key difference: Pfizer Inc pays a 6.46% dividend while ProShares Ultra Silver ETF pays none, and Pfizer Inc is trading nearer its 52-week high, ProShares Ultra Silver ETF nearer its low. Which is the better fit depends on your goals.
| AGQ | PFE | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $400.47 | $28.56 |
52-Week Low | $49.73 | $23.60 |
Market Cap | — | $151.73B |
Volume | — | 29,869,932 |
Enterprise Value | — | $203.22B |
Dividend Yield | — | 6.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AGQ, the ProShares Ultra Silver ETF, trades at $83.06, up 1.44% today, with a bullish technical signal from moving averages but overbought RSI readings. Recent news highlights its volatility, surging 9.39% on silver rallies but facing structural decay concerns due to 2x daily leverage. Financial ratios are unavailable as it is an ETF tracking silver futures.
Outlook is highly speculative, offering amplified silver exposure with significant risk. Opportunities exist if silver prices rise, but risks include leverage decay, volatility-driven losses, and silver market downturns. Investors should weigh aggressive gains against potential rapid declines.
Pfizer (PFE) trades at $27.05, up 1.16% with a bullish technical signal and consistent earnings beats in recent quarters. Revenue remains stable around $62-63 billion, though net income is projected to decline in 2026. The stock shows strong profitability margins and a solid balance sheet, but faces headwinds from patent expirations and competitive pressures.
The outlook is mixed: valuation multiples appear reasonable, and analyst consensus leans hold with a $27.86 target. Key risks include execution on pipeline catalysts and margin compression. Upside depends on successful drug launches and cost management amid a challenging revenue environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ProShares Ultra Silver ETF
AGQ is a leveraged ETF that seeks daily investment results corresponding to two times (2x) the daily performance of silver bullion. It is designed for investors seeking magnified short-term exposure to silver prices.
Read more on AGQ →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
